Epithalon (Epitalon Variant)

Research-Grade

Epithalon (also spelled Epithalon) is an alternate commercial naming for the synthetic tetrapeptide AEDG (Ala-Glu-Asp-Gly), the same active sequence as Epitalon. The naming distinction exists primarily in the research peptide market, where different vendors use different spellings. The peptide was developed by Professor Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology as a synthetic analog of the pineal gland extract Epithalamin. The proposed mechanism is telomerase activation in somatic cells — specifically, upregulation of hTERT (human telomerase reverse transcriptase) expression, which could theoretically slow or partially reverse telomere shortening. Khavinson's group has published cohort studies showing reduced cardiovascular mortality and improved biomarkers in elderly subjects receiving Epithalamin/Epithalon cycles. These studies, while internally consistent, have not been replicated by independent Western laboratories, which limits consensus acceptance. The peptide also appears to normalize circadian melatonin secretion in aged subjects, potentially through its action on pinealocytes. This secondary effect on sleep architecture may contribute to some of the reported subjective benefits.